Healthcare Business

Money background. Close-up.

Is Celgene’s Outlook Good Enough for Investors?

Celgene Corp. (NASDAQ: CELG) reported its fourth-quarter results on Thursday morning. The biotech giant did beat earnings, but investors have to weigh whether it was enough when you consider that ...
Read Full Story »
Biotechnology word cloud

Short Sellers Starting to Gang Up on Biotech

The short interest data are out for the January 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
health care

5 Stocks That May Benefit From a Terrible Flu Season

Despite the fact that the flu numbers look only slightly elevated from last year, ask almost anybody you know and either they have had it or know somebody that has. ...
Read Full Story »
Pfizer logo

Pfizer Faces Reality Check With Earnings

Pfizer Inc. (NYSE: PFE) reported its fourth-quarter results Tuesday before the markets open as $0.54 in earnings per share (EPS) and $13.1 billion in revenue. That compared to Thomson Reuters ...
Read Full Story »
Pills

Is a Generic Nexium Purple Pill for You?

When it comes to drugs being overly advertised, the Purple Pill, or Nexium, has been advertised over and over for years now. Now the question to ask is if a ...
Read Full Story »
research

3 Biotech Stocks With Upcoming Data That Could Be Huge

Binary events are often the key element in moving a biotech stock higher. Negative binary results or actions can often move shares drastically lower, though. We scan our 24/7 Wall ...
Read Full Story »
surgeons

UnitedHealth Earnings Rise as Insurer Adjusts to Obamacare

UnitedHealth Group Inc. (NYSE: UNH) reported fourth-quarter and full-year 2014 results before markets opened Wednesday. The health insurance and benefits management firm reported diluted quarterly earnings per share (EPS) of ...
Read Full Story »
Johnson & Johnson Logo

Johnson & Johnson Barely Pulls Through on Strong Pharma Sales

Johnson & Johnson (NYSE: JNJ) reported its fourth-quarter results Tuesday before the market open as $1.27 in earnings per share (EPS) on $18.6 billion in revenue. That was against Thomson ...
Read Full Story »
merck

Merck Is Top DJIA Stock in 2015

Among the 30 stocks that comprise the Dow Jones Industrial Average (DJIA), Merck & Co. Inc. (NYSE: MRK) was among the top performers in 2014, up about 14%, nearly double ...
Read Full Story »
down market

Has eHealth Fallen Too Far?

eHealth Inc. (NASDAQ: EHTH) was devastated in Thursday’s trading as the company announced its preliminary results for its fourth quarter. This appears to be a company that went from being ...
Read Full Story »
health care

Did Ziopharm and Intrexon Run Too Much on an MD Anderson Pact?

When two stocks run up over 50% and 30% on the same news, investors have to wonder if the move in the stock was justified or if the news-pop was ...
Read Full Story »
Biotechnology word cloud

Short Interest in Biotechs Signals Optimism

The short interest data are out for the December 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
462542665

Celgene Expects to More Than Triple Earnings by 2020

Celgene Corp. (NASDAQ: CELG) provided a preliminary look at its financials for 2014 but also gave its financial outlook for 2015 and far beyond at the Annual J.P. Morgan Healthcare ...
Read Full Story »
payoff

Is the Merger a Great Deal for Tekmira Shareholders?

Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), in conjunction with OnCore Biopharma, announced that they have agreed to merge and create a new global hepatitis B virus (HBV) company. The focus of ...
Read Full Story »
DNA

Has Agenus Run Too Much?

Agenus Inc. (NASDAQ: AGEN), in conjunction with Incyte Corp. (NASDAQ: INCY), announced a global license for the development and commercialization of Agenus’s proprietary Retrocyte Display antibody discovery platform. As a ...
Read Full Story »